Extended myositis-specific and -associated antibodies profile in systemic sclerosis: A cross-sectional study - 11/02/21
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 7 |
| Iconographies | 2 |
| Vidéos | 0 |
| Autres | 0 |
Highlights |
• | Myositis-specific (MSA) and -associated (MAA) antibodies in systemic sclerosis (SSc). |
• | The prevalence of MSA/MAA, MSA and MAA were 17%, 8.0% and 9.7%, respectively. |
• | The isolated prevalence of each antibody was low (inferior to 5%). |
• | MAA positivity was associated with ILD and myositis. |
• | No clinical associations were found with MSA positivity. |
Abstract |
Objective |
In systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), auto-antibodies are used in daily practice as potent biomarkers of clinical phenotypes. This study aimed at estimating the prevalence of myositis-specific (MSA) and myositis-associated (MAA) auto-antibodies in a well-characterised SSc patients cohort using two different immunoblot assays, and studying their clinical associations.
Methods |
In this cross-sectional study, the sera of 300 consecutive patients were tested at the same time with myositis antibodies Euroimmun® and D-tek® immunoblot assays.
Results |
Prevalence of MSA/MAA, MSA and MAA were 17.0%, 8.0% and 9.7%, respectively. When combining results of both tests, anti-PM/Scl 100 were found in 5.0% (95% confidence interval 2.8; 8.1); anti-PM/Scl 75 and anti-TIF1γ in 3.7% (1.8; 6.5); anti-Ku 3.0% (1.4; 5.6); anti-MDA5 in 1.3% (0.4; 3.4); anti-Mi-2 β, anti-NXP2, anti-PL-7 and anti-SRP in 0.7% (0.08; 2.4); anti-EJ and anti-PL-12 in 0.3% (0.01; 1.8) of patients. No reactivity against SAE1, Jo-1 or OJ was observed. Anti-PM/Scl 75 antibodies were associated with interstitial lung disease (80% vs. 42%) and myositis (27% vs. 3%); anti-Ku antibodies were associated with myositis (33% vs. 3%).
Conclusion |
In this cross-sectional study of 300 SSc patients, the prevalence of MSA/MAA, MSA and MAA using immunoblot assays were 17.0%, 8.0% and 9.7%, respectively. MAA positivity was associated with ILD and myositis, but this study did not highlight any clinical associations with MSA positivity.
Le texte complet de cet article est disponible en PDF.Keywords : Systemic sclerosis, Myositis-specific antibodies, Myositis-associated antibodies, Immunoblot assays
Plan
Vol 88 - N° 1
Article 105048- janvier 2021 Retour au numéro
Article précédent
- Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA
- Florenzo Iannone, Ennio G. Favalli, Roberto Caporali, Salvatore D’Angelo, Francesco Paolo Cantatore, Piercarlo Sarzi-Puttini, Rosario Foti, Fabrizio Conti, Antonio Carletto, Elisa Gremese, Alberto Cauli, Roberta Ramonda, Adalgisa Palermo, Oscar Epis, Marta Priora, Francesca Bergossi, Bruno Frediani, Fausto Salaffi, Giuseppe Lopalco, Fabio Cacciapaglia, Antonio Marchesoni, Martina Biggioggiero, Serena Bugatti, Silvia Balduzzi, Antonio Carriero, Addolorata Corrado, Sara Bongiovanni, Alessia Benenati, Francesca Miranda, Elena Fracassi, Daniela Perra, Gianfranco Ferraccioli, Giovanni Lapadula
- Comparison of paediatric and adult classification criteria in juvenile idiopathic arthritis during the transition from paediatric to adult care
- Anne-Cécile Debrach, Adrien Rougelot, Amandine Beaumel, Natalia Cabrera, Alexandre Belot, Agnès Duquesne, Bérengère Aubry-Rozier, Michael Hofer, Marie Couret, Jean-Paul Larbre, Fabienne Coury
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?